Methscopolamine bromide

Products

We are here to help in anything you need. Please use our online system or send an email to .

Methscopolamine bromide

Inquiry

Catalog Number	PR155419
CAS	155-41-9
Structure
Description	Scopolamine methobromide is a quaternary ammonium salt resulting from the reaction of the amino group of scopolamine with methyl bromide. It has a role as a muscarinic antagonist, an antiemetic, an antispasmodic drug and a parasympatholytic. It is a quaternary ammonium salt and a bromide salt. It is functionally related to a scopolamine.
Synonyms	scopolamine methyl bromide
IUPAC Name	[(1S,2S,4R,5R)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate;bromide
Molecular Weight	398.3
Molecular Formula	C18H24BrNO4
InChI	CXYRUNPLKGGUJF-OZVSTBQFSA-M
InChI Key	InChI=1S/C18H24NO4.BrH/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11;/h3-7,12-17,20H,8-10H2,1-2H3;1H/q+1;/p-1/t12?,13-,14-,15+,16-,17+;/m1./s1
Drug Categories	Agents producing tachycardia; Alkaloids; Anticholinergic Agents; Autonomic Agents; Aza Compounds; Azabicyclo Compounds; Muscarinic Antagonists; Parasympatholytics; Peripheral Nervous System Agents; Scopolamine Derivatives; Tropanes
Drug Interactions	Aclidinium-The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Aclidinium. Adenosine-The risk or severity of Tachycardia can be increased when Methscopolamine bromide is combined with Adenosine. Albuterol-The risk or severity of Tachycardia can be increased when Methscopolamine bromide is combined with Salbutamol. Alfentanil-The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Alfentanil. Alloin-The therapeutic efficacy of Alloin can be decreased when used in combination with Methscopolamine bromide.
Isomeric SMILES	C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-]
Type	Small Molecule

Pharmacology

Indications

Methscopolamine bromide is primarily indicated as an adjunctive therapy for the treatment of peptic ulcers. Additionally, it is utilized in managing nausea and vomiting associated with motion sickness.

Pharmacodynamics

As a muscarinic antagonist, methscopolamine closely resembles the neurotransmitter acetylcholine in structure and functions by inhibiting muscarinic acetylcholine receptors. This classification as an anticholinergic underlines its role in preventing motion sickness, although the exact mechanism remains unclear. The vestibular system of the inner ear plays a key role in maintaining balance, and when disrupted by motion, it sends signals to the brain's vomiting center, resulting in emesis. Methscopolamine is believed to impede this communication by blocking acetylcholine, possibly affecting the vomiting center directly. For optimal effectiveness, methscopolamine should be administered prior to the onset of motion sickness symptoms.

Absorption

Methscopolamine bromide exhibits poor and unpredictable absorption characteristics, with a total absorption rate ranging from 10% to 25%.

Mechanism of Action

Methscopolamine bromide operates by disrupting the transmission of nerve impulses mediated by acetylcholine within the parasympathetic nervous system, particularly targeting the vomiting center. This effect is achieved through its role as a muscarinic antagonist, which impedes the normal action of acetylcholine, thereby altering physiological responses associated with the parasympathetic system.

It should be noted that our service is only used for research, not for clinical use.